Adenosine 59-monophosphate-activated protein kinase regulates IL-10-mediated anti-inflammatory signaling pathways in macrophages

Journal of Immunology

Volumn 194, Issue 2, 2015, Pages 584-594

  Zhu, Yanfang Peipei ^a   Brown, Jonathan R ^a   Sag, Duygu ^b   Zhang, Lihua ^a   Suttles, Jill ^a  

^a University of Louisville School of Medicine   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE 5' MONOPHOSPHATE ACTIVATED PROTEIN KINASE ALPHA1; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 10; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SERINE; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG; AMPK ALPHA1 SUBUNIT, MOUSE; IL10 PROTEIN, MOUSE; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; STAT3 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GENE EXPRESSION; IMMUNOREGULATION; INTRACELLULAR SIGNALING; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; UPREGULATION; WILD TYPE; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-4; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84920466745     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401024     Document Type: Article

References (69)

1. Hawley, S. A., M. Davison, A. Woods, S. P. Davies, R. K. Beri, D. Carling, and D. G. Hardie. 1996. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 271: 27879-27887.
2. Hardie, D. G., J. W. Scott, D. A. Pan, and E. R. Hudson. 2003. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546: 113-120.
3. Hardie, D. G., F. A. Ross, and S. A. Hawley. 2012. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13: 251-262.
4. Sag, D., D. Carling, R. D. Stout, and J. Suttles. 2008. Adenosine 59- monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181: 8633-8641.
5. Krawczyk, C. M., T. Holowka, J. Sun, J. Blagih, E. Amiel, R. J. DeBerardinis, J. R. Cross, E. Jung, C. B. Thompson, R. G. Jones, and E. J. Pearce. 2010. Tolllike receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115: 4742-4749.
6. Carroll, K. C., B. Viollet, and J. Suttles. 2013. AMPKa1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. J. Leukoc. Biol. 94: 1113-1121.
7. Baghdadi, M., A. Yoneda, T. Yamashina, H. Nagao, Y. Komohara, S. Nagai, H. Akiba, M. Foretz, H. Yoshiyama, I. Kinoshita, et al. 2013. TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity 39: 1070-1081.
8. Yang, Z., B. B. Kahn, H. Shi, and B. Z. Xue. 2010. Macrophage alpha1 AMPactivated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem. 285: 19051-19059.
9. O'Neill, L. A., and D. G. Hardie. 2013. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493: 346-355.
10. Ouyang, W., S. Rutz, N. K. Crellin, P. A. Valdez, and S. G. Hymowitz. 2011. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29: 71-109.
11. Kühn, R., J. Löhler, D. Rennick, K. Rajewsky, and W. Muller. 1993. Interleukin- 10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
12. Croxford, J. L., M. Feldmann, Y. Chernajovsky, and D. Baker. 2001. Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: A comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J. Immunol. 166: 4124-4130.
13. Caligiuri, G., M. Rudling, V. Ollivier, M. P. Jacob, J. B. Michel, G. K. Hansson, and A. Nicoletti. 2003. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol. Med. 9: 10-17.
14. Antoniv, T. T., and L. B. Ivashkiv. 2011. Interleukin-10-induced gene expression and suppressive function are selectively modulated by the PI3K-Akt-GSK3 pathway. Immunology 132: 567-577.
15. Williams, L., L. Bradley, A. Smith, and B. Foxwell. 2004. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 172: 567-576.
16. Zhou, J. H., S. R. Broussard, K. Strle, G. G. Freund, R. W. Johnson, R. Dantzer, and K. W. Kelley. 2001. IL-10 inhibits apoptosis of promyeloid cells by activating insulin receptor substrate-2 and phosphatidylinositol 39-kinase. J. Immunol. 167: 4436-4442.
17. Inukai, K., M. Anai, E. Van Breda, T. Hosaka, H. Katagiri, M. Funaki, Y. Fukushima, T. Ogihara, Y. Yazaki, Y. Kikuchi, et al. 1996. A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. J. Biol. Chem. 271: 5317-5320.
18. Xia, X., A. Cheng, D. Akinmade, and A. W. Hamburger. 2003. The N-terminal 24 amino acids of the p55 gamma regulatory subunit of phosphoinositide 3-kinase binds Rb and induces cell cycle arrest. Mol. Cell. Biol. 23: 1717-1725.
19. Wang, G. H., X. L. Luo, L. Sun, Y. Deng, X. L. Li, D. D. Tao, J. B. Hu, and J. P. Gong. 2008. [Inhibitory effect of N-terminal 24 amino acids of the p55 gamma, a regulatory subunit of phosphoinositide 3-kinase, on proliferation of colon carcinoma cell line HT29]. Ai Zheng 27: 1034-1038.
20. Alessi, D. R., and P. Cohen. 1998. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 8: 55-62.
21. Alessi, D. R., M. Andjelkovic, B. Caudwell, P. Cron, N. Morrice, P. Cohen, and B. A. Hemmings. 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15: 6541-6551.
22. Navé, B. T., M. Ouwens, D. J. Withers, D. R. Alessi, and P. R. Shepherd. 1999. Mammalian target of rapamycin is a direct target for protein kinase B: Identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344: 427-431.
23. Crawley, J. B., L. M. Williams, T. Mander, F. M. Brennan, and B. M. Foxwell. 1996. Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. J. Biol. Chem. 271: 16357-16362.
24. Williams, L. M., G. Ricchetti, U. Sarma, T. Smallie, and B. M. Foxwell. 2004. Interleukin-10 suppression of myeloid cell activation-a continuing puzzle. Immunology 113: 281-292.
25. Murray, P. J. 2007. The JAK-STAT signaling pathway: Input and output integration. J. Immunol. 178: 2623-2629.
26. Finbloom, D. S., and K. D. Winestock. 1995. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J. Immunol. 155: 1079-1090.
27. Decker, T., and P. Kovarik. 2000. Serine phosphorylation of STATs. Oncogene 19: 2628-2637.
28. Zhang, X., J. Blenis, H. C. Li, C. Schindler, and S. Chen-Kiang. 1995. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 267: 1990-1994.
29. Wen, Z., Z. Zhong, and J. E. Darnell Jr. 1995. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241-250.
30. Riley, J. K., K. Takeda, S. Akira, and R. D. Schreiber. 1999. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem. 274: 16513-16521.
31. Yokogami, K., S. Wakisaka, J. Avruch, and S. A. Reeves. 2000. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol. 10: 47-50.
32. Kim, J. H., J. E. Kim, H. Y. Liu, W. Cao, and J. Chen. 2008. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J. Biol. Chem. 283: 708-715.
33. Kim, J. H., M. S. Yoon, and J. Chen. 2009. Signal transducer and activator of transcription 3 (STAT3) mediates amino acid inhibition of insulin signaling through serine 727 phosphorylation. J. Biol. Chem. 284: 35425-35432.
34. Donnelly, R. P., H. Dickensheets, and D. S. Finbloom. 1999. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J. Interferon Cytokine Res. 19: 563-573.
35. Hutchins, A. P., D. Diez, and D. Miranda-Saavedra. 2013. The IL-10/STAT3- mediated anti-inflammatory response: recent developments and future challenges. Brief Funct. Genomics 12: 489-498.
36. Weichhart, T., M. Haidinger, K. Katholnig, C. Kopecky, M. Poglitsch, C. Lassnig, M. Rosner, G. J. Zlabinger, M. Hengstschläger, M. Muller, et al. 2011. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 117: 4273-4283.
37. Inoki, K., T. Zhu, and K. L. Guan. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
38. Guo, L., J. L. Stripay, X. Zhang, R. D. Collage, M. Hulver, E. H. Carchman, G. M. Howell, B. S. Zuckerbraun, J. S. Lee, and M. R. Rosengart. 2013. CaMKIa regulates AMP kinase-dependent, TORC-1-independent autophagy during lipopolysaccharide-induced acute lung neutrophilic inflammation. J. Immunol. 190: 3620-3628.
39. Viollet, B., F. Andreelli, S. B. Jørgensen, C. Perrin, D. Flamez, J. Mu, J. F. Wojtaszewski, F. C. Schuit, M. Birnbaum, E. Richter, et al. 2003. Physiological role of AMP-activated protein kinase (AMPK): Insights from knockout mouse models. Biochem. Soc. Trans. 31: 216-219.
40. Reynolds, J. M., Q. Liu, K. C. Brittingham, Y. Liu, M. Gruenthal, C. Z. Gorgun, G. S. Hotamisligil, R. D. Stout, and J. Suttles. 2007. Deficiency of fatty acidbinding proteins in mice confers protection from development of experimental autoimmune encephalomyelitis. J. Immunol. 179: 313-321.
41. Murray, P. J., J. E. Allen, S. K. Biswas, E. A. Fisher, D. W. Gilroy, S. Goerdt, S. Gordon, J. A. Hamilton, L. B. Ivashkiv, T. Lawrence, et al. 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41: 14-20.
42. Pfaffl, M. W., G.W. Horgan, and L. Dempfle. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30: e36.
43. Lang, R., D. Patel, J. J. Morris, R. L. Rutschman, and P. J. Murray. 2002. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169: 2253-2263.
44. Han, X., S. Kitamoto, H. Wang, and W. A. Boisvert. 2010. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J. 24: 2869-2880.
45. Ewart, M. A., and S. Kennedy. 2011. AMPK and vasculoprotection. Pharmacol. Ther. 131: 242-253.
46. Plump, A. S., and J. L. Breslow. 1995. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu. Rev. Nutr. 15: 495-518.
47. Murray, P. J. 2006. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Opin. Pharmacol. 6: 379- 386.
48. Tolloczko, B., P. Turkewitsch, M. Al-Chalabi, and J. G. Martin. 2004. LY- 294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] affects calcium signaling in airway smooth muscle cells independently of phosphoinositide 3- kinase inhibition. J. Pharmacol. Exp. Ther. 311: 787-793.
49. 2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2: 21-33.
50. Zhang, Y., X. Wang, H. Yang, H. Liu, Y. Lu, L. Han, and G. Liu. 2013. Kinase AKT controls innate immune cell development and function. Immunology 140: 143-152.
51. Inoki, K., Y. Li, T. Zhu, J. Wu, and K. L. Guan. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4: 648-657.
52. Manning, B. D., A. R. Tee, M. N. Logsdon, J. Blenis, and L. C. Cantley. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10: 151-162.
53. Berlato, C., M. A. Cassatella, I. Kinjyo, L. Gatto, A. Yoshimura, and F. Bazzoni. 2002. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J. Immunol. 168: 6404-6411.
54. Qasimi, P., A. Ming-Lum, A. Ghanipour, C. J. Ong, M. E. Cox, J. Ihle, N. Cacalano, A. Yoshimura, and A. L. Mui. 2006. Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages. J. Biol. Chem. 281: 6316- 6324.
55. Tokumitsu, H., H. Inuzuka, Y. Ishikawa, M. Ikeda, I. Saji, and R. Kobayashi. 2002. STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J. Biol. Chem. 277: 15813-15818.
56. Williams, L. M., U. Sarma, K. Willets, T. Smallie, F. Brennan, and B. M. Foxwell. 2007. Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J. Biol. Chem. 282: 6965-6975.
57. Takeda, K., B. E. Clausen, T. Kaisho, T. Tsujimura, N. Terada, I. Förster, and S. Akira. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.
58. Qin, H., A. T. Holdbrooks, Y. Liu, S. L. Reynolds, L. L. Yanagisawa, and E. N. Benveniste. 2012. SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J. Immunol. 189: 3439-3448.
59. Stout, R. D., and J. Suttles. 2004. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J. Leukoc. Biol. 76: 509- 513.
60. Stout, R. D., C. Jiang, B. Matta, I. Tietzel, S. K. Watkins, and J. Suttles. 2005. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175: 342-349.
61. Locati, M., A. Mantovani, and A. Sica. 2013. Macrophage activation and polarization as an adaptive component of innate immunity. Adv. Immunol. 120: 163-184.
62. Zhou, D., C. Huang, Z. Lin, S. Zhan, L. Kong, C. Fang, and J. Li. 2014. Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell. Signal. 26: 192-197.
63. Raffai, R. L. 2012. Apolipoprotein E regulation of myeloid cell plasticity in atherosclerosis. Curr. Opin. Lipidol. 23: 471-478.
64. Longnus, S. L., C. Ségalen, J. Giudicelli, M. P. Sajan, R. V. Farese, and E. Van Obberghen. 2005. Insulin signalling downstream of protein kinase B is potentiated by 5'AMP-activated protein kinase in rat hearts in vivo. Diabetologia 48: 2591-2601.
65. Jacinto, E., V. Facchinetti, D. Liu, N. Soto, S. Wei, S. Y. Jung, Q. Huang, J. Qin, and B. Su. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137.
66. Liu, Y., K. N. Stewart, E. Bishop, C. J. Marek, D. C. Kluth, A. J. Rees, and H. M. Wilson. 2008. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J. Immunol. 180: 6270-6278.
67. Zhou, L., A. A. Nazarian, and S. T. Smale. 2004. Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol. Cell. Biol. 24: 2385-2396.
68. Kobayashi, T., K. Matsuoka, S. Z. Sheikh, S. M. Russo, Y. Mishima, C. Collins, E. F. deZoeten, C. L. Karp, J. P. Ting, R. B. Sartor, and S. E. Plevy. 2012. IL-10 regulates Il12b expression via histone deacetylation: Implications for intestinal macrophage homeostasis. J. Immunol. 189: 1792-1799.
69. Smith, A. M., J. E. Qualls, K. O'Brien, L. Balouzian, P. F. Johnson, S. Schultz- Cherry, S. T. Smale, and P. J. Murray. 2011. A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) protein NFIL3. J. Biol. Chem. 286: 23582-23590.